A Phase 4 interventional study of dermo cosmetic product in Hypotrichosis, sponsored by Quantum Aesthetics Cosmetics. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by Quantum Aesthetics Cosmetics · Phase 4, Interventional, and Treatment
Efficacy and Safety of Dallixa® Eyelash Serum in Idiopathic Eyelash Hypotrichosis
24 studies on the registry are indexed under Hypotrichosis; 2 are open to participants now.
This study's enrollment of 37 is below the median of 56 across 22 interventional studies indexed under Hypotrichosis.
Browse Hypotrichosis studies →Quantum Aesthetics Cosmetics is the lead sponsor of 2 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Eyelash prominence assessment of minimal or moderate
- A score of 1 or 2 on the clinician-graded Global Eyelash Assessment (GEA)
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: dermo cosmetic product
dermo cosmetic products like herbal or vitamin ingredients
The proportion of subjects with ≥ 1-grade increase in the GEA at month 4
Time frame: 4 month
The proportion of subjects with ≥ 1-grade increase in the GEA at month 2
Time frame: 2month
The proportion of subjects with ≥ 2-grade increase in the GEA at month 2 and 4
Time frame: at2 and4 month
Change from baseline in upper eyelash length (mm) at month 2 and 4 (Based on DIA)
Time frame: at 2 and 4 month
Change from baseline in average progressive upper eyelash thickness (mm2) at month 2 and 4 (Based on DIA)
Time frame: at 2 and 4 month
Percentage of Participants Satisfied or Very Satisfied in the Patient's Assessment of Overall Eyelash Satisfaction as Measured by the Eyelash Satisfaction Questionnaire (ESQ-9) at month 2 and 4
Time frame: at 2 and4 month
Adverse events reported from the baseline and during the study period (from the baseline up to week 16)
Time frame: from the baseline up to week 16
Plan to share: No — no plan to share the individual participant data yet
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Quantum Aesthetics Cosmetics